Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

Pacific Biosciences and Sage Science Announce Co-Marketing Partnership

Thursday, May 16, 2013

PacBio® RS II With BluePippin™ Size Selection Platform Provides Customers Improved Ability to Sequence Longer DNA Fragments

MENLO PARK, Calif. and BEVERLY, Mass., May 16, 2013 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc., (Nasdaq:PACB), provider of the PacBio® RS II DNA Sequencing System, and Sage Science, a developer of life science products for improving sample preparation processes in molecular biology applications, today announced a co-marketing partnership to provide customers of the PacBio RS II the ability to sequence even longer DNA fragments when performing Single Molecule, Real-Time (SMRT®) Sequencing.

“We have found that the BluePippin™ size selection platform is very useful for applications where long read lengths are important, such as de novo genome assembly,” said Kevin Corcoran, Senior Vice President of Market Development at Pacific Biosciences. “Our studies have demonstrated that size selection with Sage’s BluePippin platform is an easy addition to our customers’ sample prep workflow that selects for 10 kb or larger fragments for sequencing on the PacBio RS II.”

Based on PacBio’s revolutionary SMRT Sequencing technology, the PacBio RS II can generate average read lengths of 5,000 base pairs, with the longest reads above 20,000 base pairs in length. The PacBio RS II System, including consumables and software, provides a simple, fast, end-to-end workflow for SMRT Sequencing in research areas including infectious disease and microbiology, agriculture, and complex genetic diseases with repeat expansions.

The BluePippin platform, part of the Pippin line of automated size-selection tools offered by Sage Science, uses pulsed-field power to take fractions of DNA from fragments ranging from 50 bases to 50 kilobases. Independent studies of size-selection methods for next-generation sequencing sample prep have repeatedly found that the Pippin platform offers unparalleled reproducibility, accuracy, and sample recovery. By eliminating low-molecular-weight templates from sequencing libraries, automated size selection allows users to load longer fragments and boost the average read length produced by sequencing.

“This is excellent validation of the tremendous utility BluePippin offers for libraries designed to generate extraordinarily long sequence reads,” said Alex Vira, Director of Marketing for Sage Science. “We look forward to working with PacBio and its customers as they continue to deliver industry-leading read lengths and conduct countless studies that would be impossible with shorter-read technologies.”

In data presented at the Advances in Genome Biology & Technology conference earlier this year, Pacific Biosciences scientists assessed three libraries (bacterial, fish and mammalian) generated with and without BluePippin size selection. They reported that N50 subread lengths increased by 90%, 110%, and 86%, respectively, in the libraries that were size selected with BluePippin compared to those that were not.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio® RS II DNA Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, the company’s products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. More information is available at www.pacb.com.

About Sage Science

Sage Science is a privately held company based in Beverly, Mass., that develops life sciences products to ease the burden and improve the quality of sample preparation processes for molecular biology applications. Its Pippin product line, including the Pippin Prep and BluePippin, offers scientists a highly reproducible, automated alternative to manual gels for DNA size selection and purification that significantly reduces hands-on time while yielding more precise genomic libraries. For more information, visit www.sagescience.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, explicit or implied, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “potential,” “believes,” “goal,” “estimate,” “anticipates,” “outlook,” and similar words. These statements are based on the current estimates and assumptions of Pacific Biosciences’ management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the speed,
potential usefulness, ease of use and read lengths achieved in applications of the PacBio RS II DNA Sequencing System and the reproducibility, accuracy and sample recovery of the Pippen platform, as well as the ease of ability to incorporate the Pippin platform with sequencing on the PacBio RS II. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks more fully described in the “Risk Factors” section of Pacific Biosciences’ most recently filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and the risks discussed in Pacific Biosciences’ other reports filed with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. Pacific Biosciences undertakes no
obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

CONTACT: For Pacific Biosciences:


         Maurissa Messier

         For Pacific Biosciences




         Trevin Rard

         Pacific Biosciences



         For Sage Science:

         Alex Vira



Source: Pacific Biosciences of California, Inc.; Sage Science

News Provided by Acquire Media

Press Release

PacBio Grants Equity Incentive Award to New Employee

Friday, January 14, 2022


Visit our blog »